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Abstract 
 
A pure ovarian choriocarcinoma is a very rare disease which can be either pregnancy related (gestational), may not 
be related (non-gestational), or commonly correlated with different type of germ cell; teratocarcinoma, 
dysgerminoma or undifferentiated carcinoma. A pure non-gestational primary ovarian choriocarcinoma is 
astronomically uncommon and we recorded such condition in 14-year-old teenage girl’s ovary. An abdominal 
operative procedure with the help of a careful histopathology examination revealed choriocarcinoma in absence of 
other type of germ cell element. Multiple courses of Etoposide/Methotrexate/Actinomycin-D (EMA) regime of 
chemotherapy were shown to be effective in this case. 
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Introduction 
 
Among the spectrums of gestational trophoblastic 
disease (GTD) is choriocarcinoma. It is labeled as an 
uncommon malignant tumour that can be either 
gestational or non-gestational type. The gestational type 
actually depends on the contents of at least a paternal 
chromosome whereas the non-gestational type usually 
comes about from the ovarian germ cell tumors (GCTs) 
without paternal genetic influence. We are presenting a 
case of pure non-gestational primary ovarian carcinoma 
in 14-year-old teenager with metastasis to the small 
bowel mesentery, appendix, bladder and pelvic lymph 
nodes. 
 
Case Report 
 
A 14-year- old, single, non-sexually active teenage girl 
presented to Gynecology Department after being 
referred in by a General Practitioner (GP) for complex 
abdominal mass associated with loss of appetite, 
compressive symptoms and occasionally low-grade 
fever for two-month duration.  
 
Clinically, there was a fixed pelvic mass that 
corresponded to 20-weeks pregnancy with smooth 
mucosa per-rectally. A pelvic ultrasound indicated a 
massive complex mass measuring 13.4 cm x 11.2 cm 
with thick wall comprising cystic and solid elements 
including papillary projection and minimal free fluid. 
The uterus was empty and the left kidney was normal. 
Right kidney appeared hydronephrotic. An abdominal 
computed tomography (CT) scan indicated a huge 
heterogeneous mass measuring 17.6 cm x 14 cm with 
bilateral mild hydronephrosis of the kidney associated 
with 1 cm para-aortic nodes which concluded 
carcinoma of ovary with peritoneal and para aortic 
metastases. Pre-operative serum tumour markers were 
taken and indicated a marked increase in the level of 
human chorionic gonadotropins (BHCG) level 169348.30  
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Figure 1: Negative for placental-like alkaline phosphatase 
(PLAP) and AFP  
 
 
Figure 2: Positive test with B-CHG and CK7 
 
 
 
Figure 3: Decrease in HCG level after surgery and EMA 
regime. 
 
(normal <1.2) and cancer antigen 125 (CA125) was 
173.6 (normal 0-35 iu/l). Other markers such as 
carcinoembryonic antigen (CEA) were 2.43 and Alpha 
feto-protein (AFP) was 0.6.  
 
She underwent a left salphingoophorectomy with 
infragastricomentectomy, debulking and 
appendicectomy.  At laparotomy, a huge left ovarian 
tumour was seen and appeared to be densely adhered to 
a small bowel, sigmoid colon, pelvic peritoneal, bladder 
and also appendix. It was entirely removed. Optimal 
debulking was accomplished without any macroscopic 
indication of extra-ovarian malady. Pelvic lymph nodes 
were inspected which revealed the enlargement of the 
left external iliac lymph nodes (LN), omental LN and 
small bowel mesentery LN. The para aortic LN was not 
enlarged. The uterus, right ovary and tubes were 
normal. The Histology Pathological Examination (HPE) 
result showed an evidence of positive test with B-CHG 
and CK7 and negative for placental-like alkaline 
phosphatase (PLAP) and AFP consistent with pure 
ovarian choriocarcinoma with no association with other 
possible germ cell tumour. The lymphovascular 
invasion was observed with metastasis evidence to 
appendix, small bowel mesentery and left external iliac 
LN. In view of her extensive disease and the 
histological findings, she was planned for EMA 
(Etoposide/Methotrexate/Actinomycin-D) for first cycle 
and EMA plus CO (Vicristine/ Cyclophosphomide) 
chemotherapy regimes for second cycle.  
 
After four weeks following these two cycles of 
chemotherapy, the level of HCG reduced significantly 
from 14608.10, post-operatively to 1718 for the first 
cycle and further plummeted to 99.31 following the 
second cycle. However, her liver enzymes were 
observed to be deranged after the additional of CO 
regimes in second chemotherapy cycle. Therefore, she 
was continued with only EMA regime in view of lesser 
side effect and responded well by evidence of reduction 
of HCG level during follow-up. She had been under a 
follow-up treatment for almost 18 months at present and 
had undergone up to a total of seven cycles of EMA 
chemotherapy.  She is currently on a remission state 
with the latest CT scan had shown no evidence of 
recurrence or metastasis and latest HCG was <1.2. She 
was scheduled for 3-monthly outpatient reviews with 
HCG level monitoring. 
 
Discussion 
 
A pure non-gestational ovarian carcinoma (NGOC) is 
extremely rare as reported by Hay & Steward in 1969, 
Panayaton et al. in 1971 and A Oladipo et al. in 2007 
(1,2,3). This condition is usually diagnosed in pre-
pubertal female. In reproductive age group who is non-
sexually active, it may be suspected clinically but the 
definitive diagnosis required a specific DNA 
polymorphism test to histologically determine the 
paternal alleles in the tumor (4,5,6,7). However, a 
conclusive literature review including PubMed and 
Medline demonstrates as few as five cases reported with 
NGOC diagnosed utilizing this test while others 43 
cases reported only based on sexual history given the 
non-availability of the test.  
 
It is important to determine this two main sub group of 
ovarian choriocarcinoma, as the gestational ovarian 
Pure nongestational ovarian choriocarcinoma                                                                                                       Mohd Faizal A et al. 
 
Journal of Surgical Academia 2015; 5(1): 51-53   53 
 
choriocarcinoma (GOC) type is a more common 
condition with better chemotherapy option, good 
prognostic and less aggressive disease. The latter was 
reported about 25% and is associated with normal 
pregnancy and abortion and about 50% following molar 
pregnancy. This is because HCG increases 1000-2000 
folds chances to manifest this condition. The GOC 
commonly metastasizes to lungs and brain. It is 
effectively treated with Methotrexate (MTX) based 
chemotherapy regime such as EMA, EMA/CO and EP 
/EMA. On the other hand, the NGOC is extremely rare 
condition. It was reported by Goswami et al. (8) that the 
mean age of incidence is 13.6 +/- 6.9 years old and 
usually presented with pelvic mass associated with 
nausea, vomiting and amenorrhea. There is no specific 
management guideline for chemotherapy option to date 
and usually associated with poor prognosis due to very 
aggressive disease. Pentheroudakis G et al. in 2004 (9) 
reported that they usually required a highly 
mylosupressive chemotherapy regime in order to 
control the progression of the disease and yield a better 
prognosis.  
 
In this case, she was diagnosed as pure - NGOC based 
on the background of sexual history alone. There was 
no DNA polymorphism test was carried out due to non-
availability of the test.  We reported that this 16-year 
old teenage girl was successfully treated with 
conservative cytoreductive surgery and EMA 
chemotherapy regime alone that results in excellent 
responses. This case was considered unusual as 
previously reported that NGOC was usually aggressive 
and not responding well to MTX based chemotherapy 
alone. Therefore, we concluded that the mainstay 
treatment for this condition is by case-to-case basis 
depending on medical personnel experiences and patient 
condition during the first presentation. The type of 
surgical excision, thorough histological evaluation of all 
elements present and patient general condition also 
contributed to determine the choice of combination 
chemotherapy. Our case shows that conservative cyto-
reduction type of surgery in tandem with post-operative 
EMA chemotherapy may be an efficacious therapeutic 
treatment for pure ovarian non-gestational 
choriocarcinoma in young girl. Taking into account that 
pure ovarian choriocarcinoma is aggressive with a high 
risk of metastasis and recurrence; we recommend a 
thorough follow-up treatment with serum HCG and 
imaging examinations as key to the success in managing 
this condition. 
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